Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes
The European Patent Office (EPO) has informed Diamyd Medical that the patent application protecting the use of insulin-based antigens for the treatment of autoimmune diabetes in patients carrying the HLA DR4-DQ8 genetic marker will be granted. The patent, valid until 2035, marks an important step in advancing precision medicine for diabetes care.The forthcoming EPO patent grant builds on the foundation already established for patients with the HLA DR3-DQ2 genotype, a distinct genetic subgroup currently targeted by Diamyd Medical’s GAD-specific immunotherapy Diamyd[®] in the ongoing Phase 3